CD4+ CD25+ Tregs act in a regulatory capacity by suppressing the activation and function of other immunocytes, they can control immune responses induced by DCs in vivo [18], also prevent CD8+ T cell maturation by inhibiting CD4+ Th cells at tumor sites [19]. The gene discussed is IL2RA; the disease is neoplasm.